Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025
November 11, 2025 – Biotechnology, Clinical Trials, Other, Pharmaceutical – Acuitas Therapeutics, LNP delivery platforms, gene therapy, lipid nanoparticle platforms, vaccines
29 October 2025 — British Columbia, Canada — Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025. The company will present its latest advancements in LNP technology, highlighting its role in the development of next-generation therapeutic solutions, including vaccines and gene therapies, and underscoring its commitment to robust scientific validation.
“We’re excited to share our latest research and connect with our colleagues around the world at
these important events,” said Dr. Ying Tam, Chief Scientific Officer of Acuitas Therapeutics. “Our
participation in these conferences provides an excellent opportunity to showcase the versatility
and potential of our LNP platform to fully enable mRNA-based medicines to address a wide range
of diseases.”
Conference Presentation Schedule:
1. Vaccines Research & Development — November 5-7, Boston, MA
Oral Presentation Title: Novel Lipids With Improved Activity For Prophylactic Vaccine Development
Presentation Time: November 6th, 2025
Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
Panel Presentation: Rapid Response Platforms for Outbreaks & Pandemic Preparedness
Presentation Time: November 5th, 2025
Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
Poster Presentation Title: Development of mRNA-LNP for Cancer Vaccine
Presentation Time: November 5th, 2025
Presenter: Dr. Fan Yan, Research Scientist II
2. mRNA Health Conference — November 11-13, Berlin, Germany
Oral Presentation Title: Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics
Presentation Time: November 12th, 2025
Presenter: Dr. Ying Tam, Chief Scientific Officer
Poster Title: Effects of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medication on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys
Presentation Time: November 11th, 2025
Presenter: Dr. Sherry Weppler, Sr. Research Scientist I
Poster Title: Development of mRNA-LNP for Cancer Vaccine
Presentation Time: November 11th, 2025
Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
Poster Title: Novel Lipids with Improved Activity For Prophylactic Vaccine Development
Presentation Time: November 12th, 2025
Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
Conference Attendance Schedule:
- BIO Europe Fall — November 3-5, Vienna, Austria
- Breakthroughs in Targeted In Vivo Gene Therapy — November 20-21, San Diego, CA
More information about these conferences is available at the organizers’ websites. Acuitas’
presented posters will be available on the presentations page after the respective conference
concludes.
About Acuitas Therapeutics
Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing
lipid nanoparticle (LNP) delivery systems for nucleic acid based therapeutics. They collaborate
with pharmaceutical and biotech companies, academic researchers, and global health
organizations to advance a broad range of medicines for a variety of diseases. Acuitas’ clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. The technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy. Today, they are advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines. For more information, visit www.acuitastx.com
